Citadel Advisors’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Citadel Advisors’s Portfolio STAB Stock Details STAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,368	Closed	-$5.27K	–	14669
2022 Q1	$7K	Buy	+20,368	New	+$21.8K	﹤0.01%	13407
2021 Q2	–	Sell	-36,626	Closed	-$192K	–	14740
2021 Q1	$192K	Buy	36,626 +25,471	+228%	+$139K	﹤0.01%	11753
2020 Q4	$38K	Buy	+11,155	New	+$31.8K	﹤0.01%	10664
2020 Q2	–	Sell	-12,009	Closed	-$20K	–	10739
2020 Q1	$20K	Buy	+12,009	New	+$24.5K	﹤0.01%	9306
2019 Q4	–	Sell	-28,435	Closed	-$29K	–	9984
2019 Q3	$29K	Buy	+28,435	New	+$38.3K	﹤0.01%	8860
2018 Q3	–	Sell	-15,389	Closed	-$38K	–	9869
2018 Q2	$38K	Buy	15,389 +1,888	+14%	+$5.25K	﹤0.01%	8496
2018 Q1	$41K	Buy	+13,501	New	+$47.6K	﹤0.01%	7983
2017 Q4	–	Sell	-10,032	Closed	-$35K	–	8593
2017 Q3	$35K	Sell	10,032 -5,686	-36%	-$16.1K	﹤0.01%	7260
2017 Q2	$46K	Buy	+15,718	New	+$51.4K	﹤0.01%	7116
2016 Q4	–	Sell	-29,899	Closed	-$52K	–	8038
2016 Q3	$52K	Buy	+29,899	New	+$65.7K	﹤0.01%	6843
2014 Q4	–	Sell	-2,386	Closed	-$22K	–	8813
2014 Q3	$22K	Buy	+2,386	New	+$21.9K	﹤0.01%	7367
2014 Q1	–	Sell	-427	Closed	-$10K	–	8072
2013 Q4	$10K	Sell	427 -158	-27%	-$4.3K	﹤0.01%	6710
2013 Q3	$18K	Buy	585 +273	+88%	+$9.03K	﹤0.01%	6275
2013 Q2	$10K	Buy	+312	New	+$10.7K	﹤0.01%	6242

Other funds holding STAB

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's STAB Position: Q2 2022 in Review

Citadel Advisors sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q2 2022, closing a stake of 20,368 shares — an estimated $5.27K sold.

Citadel Advisors first reported a position in STAB in Q2 2013 and held it in 14 quarters. The position peaked at $192K in Q1 2021. 35 funds tracked by Wall St. Rank hold STAB as of Q2 2022.

Citadel Advisors reported no remaining Statera Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Citadel Advisors sold 20,368 Statera Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $5.27K.
Citadel Advisors first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2013 and held it in 14 quarters.
Citadel Advisors's Statera Biopharma, Inc. Common Stock position peaked at $192K in Q1 2021.
35 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.